Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- UMN, API, Yakult Officially Agree on Joint Biosimilar Business
June 24, 2013
- Toho Holdings Targets 26.1 Billion Yen Operating Profit in FY2015
June 24, 2013
- Volibris Receives Orphan Drug Designation for Indication of CTEPH in Japan: GSK
June 24, 2013
- Kowa, Sanofi File NDAs for SGLT-2 Inhibitor Tofogliflozin in Japan
June 24, 2013
- Kitasato Daiichi Sankyo Vaccine Submits NDA for Cell-Based Pandemic Flu Vaccine
June 24, 2013
- Industry FTC Finds Only 1 Violation of New Rules on Settai in FY2012 Following Their Introduction
June 21, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 2: Explanations to the World Urged
June 21, 2013
- MSD Revives “US Training” Program to Enhance Skills of Outstanding MRs
June 21, 2013
- Baxter Receives Approval for Cell-Based H5N1 Vaccine
June 20, 2013
- Daiichi Sankyo Files NDA for Next Mainstay Product Prasugrel in Japan
June 20, 2013
- AZ, BMKK Aim to Develop Market for Bydureon as Drug before Insulin
June 20, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 1: A Blurred Line
June 20, 2013
- Takeda’s 3 Nesina Family Drugs Make US Debut
June 19, 2013
- MSD to Continue Efforts for HPV Vaccine Recommendation
June 19, 2013
- Novartis Pharma to Voluntarily Refrain from Participation in JPMA’s Board of Directors Meeting
June 19, 2013
- Chairman Kato Resigns, to Move to Specially Appointed Professor Position at University of Tokyo: AZ
June 19, 2013
- GSK Says No Evidence Shows Causal Link between HPV Vaccines and Serious Adverse Events
June 18, 2013
- Shionogi Signs MOU on R&D with Six Universities in Ireland
June 18, 2013
- Eisai to Expand Packaging Facility at UK Plant, Eying Lenvatinib Launch
June 18, 2013
- Takeda, Pfizer Settle Protonix Patent Lawsuit with Teva, Sun for US$2.15 Billion
June 17, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…